-

FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET).

EBTATE is used in Precision Medicine for Targeted Radionuclide Therapy. The key feature of this technology is the appendage of Evans blue (EB) to the targeting radiopharmaceutical. EB binds reversibly to serum albumin to enhance the radiotherapeutic time window with longer circulation half-life and increase tumor uptake/retention to improve therapeutic outcome.

Dr. Chris Pak, President & CEO of MTTI commented: “The clearance of our IND is an important milestone for MTTI. Having solidified our clinical trial preparedness and manufacturing readiness, we are well-positioned to advance EBTATE. The upcoming trial is an open-label, dose-escalation study planned for patients with neuroendocrine tumors (NET).”

Molecular Targeting Technologies, Inc. is a privately held, clinical stage biotech company, developing targeted radiotherapeutics and diagnostics for rare cancers. MTTI has received an exclusive worldwide license from the National Institutes of Health to commercialize selected targeted radiopharmaceuticals covered by their Evans blue (EB) platform technology patents. This transformative technology has potential applications for other types of cancer patients overexpressing somatostatin receptor type 2 (SSTR2), such as Hürthle Cell Thyroid Carcinoma. The company is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical therapy assets to improve human health, reduce healthcare costs and reward stakeholders. It contracts with ClinSmart as a Clinical Research Organization (Newtown, PA). MTTI expects to orchestrate multiple clinical trials in 2021. For more information: www.mtarget.com

Contacts

Chris Pak, Email: cpak@mtarget.com; Tel: 610-738-7938

Industry:

Molecular Targeting Technologies, Inc.

Release Summary
FDA approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
Release Versions
English

Contacts

Chris Pak, Email: cpak@mtarget.com; Tel: 610-738-7938

More News From Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Targeted Radiotherapeutic (EB-TRT)

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) has filed a formal legal complaint in the Court of Common Pleas for Chester County, Pennsylvania concerning the unauthorized use of its EB-TRT technology by Dr. Xiaoyuan (Shawn) Chen, a former consultant who had previously worked with the company in a professional capacity pursuant to a consulting services agreement. During his engagement with MTTI, Dr. Chen was granted access to proprietary EB-TRT technology unde...

MTTI Announces Dr. Danielle Meyrick to Lead Medical Team

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) today announced the appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer. Dr. Meyrick brings more than 20 years of medical research, targeted radiotherapeutic (TRT) development and leadership to MTTI. She has held Chief Medical Officer roles across radiopharmaceutical organizations including Telix Pharmaceuticals and ITM Radiopharm. Dr. Meyrick will lead MTTI’s medical team to advance clinical develo...

MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary 225Ac-EBTATE against SSTR2 NET cancers online in the European Journal of Nuclear Medicine. (“Long acting 225Ac-EBTATE is highly efficacious against somatostatin receptor-2-positive neuroendocrine tumors” (https://rdcu.be/d2lCG). Professor Humphrey Fonge of the Université de Laval and lead author commented, “At just 40% of the administered dose reported for...
Back to Newsroom